IP Library Granted Patent US 7,381,421
Granted Patent B2
US 7,381,421 · App. 10/149,670 · Granted Jun 3, 2008

Liposomes

Assignee: Lipoxen Technologies Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,381,421
App. No.
10/149,670
Granted
Jun 3, 2008
Kind
B2
Abstract

Polyanionic therapeutic compounds, generally nucleic acids, are complexed with calcium phosphate and entrapped within liposomes. For DNA vaccines, the complexation and entrapment process provides improved immune response for gene vaccines delivered intramuscularly.

Claims (21)

1. A method of inducing an immune response in a human or animal body, which method comprises

administering to said body a composition of liposomes formed of liposome forming components which consist of compounds having no overall charge,

wherein said liposomes have entrapped within the interior space, a complex of a nucleic acid compound having a molecular weight of at least 1000 D and calcium phosphate, wherein the ratio of calcium phosphate to nucleic acid is in the range 1 mole Ca 2+ :(1-4)g nucleic acid,

and wherein the nucleic acid compound is DNA operatively encoding antigen.

2. The method according to claim 1 in which the liposome forming components include cholesterol.

3. The method according to claim 1 in which the liposome forming components include cholesterol.

4. The method according to claim 1 in which the liposome forming components include one or more phosphatidyl cholines, optionally in combination with phosphatidyl ethanolamine.

5. The method according to claim 1 in which the interior space includes also a sugar.

6. The method according to claim 5 in which the sugar is a mono- or di-saccharide.

7. The method according to claim 1 in which the liposomes have an average diameter in the range 100 nm-5 μm.

8. The method according to claim 7 in which the liposomes have an average diameter in the range 200 nm-1 μm.

9. The method according to claim 1 in which the liposomes are in combination with a pharmaceutical acceptable excipient.

10. The method according to claim 1 suspended in a continuous aqueous vehicle.

11. A method of inducing an IgG immune response in a human or animal body wherein said method comprises

administering to said body a composition of liposomes formed of liposome forming components which consist of compounds having no overall charge,

wherein said liposomes have entrapped within the interior space, a complex of a nucleic acid compound having a molecular weight of at least 1000 D and calcium phosphate, wherein the ratio of calcium phosphate to nucleic acid is in the range 1 mole Ca 2+ :(1-4)g nucleic acid, and

wherein the nucleic acid compound is DNA operatively encoding antigen.

12. The method according to claim 11 wherein the antigen is a peptide antigen and in which the composition is administered intramuscularly.

13. The method according to claim 11 wherein liposome forming components include one or more phosphatidyl cholines, optionally in combination with phosphatidyl ethanolamine.

14. The method according to claim 11 wherein the interior space includes a mono- or di-saccharide.

15. The method according to claim 11 wherein the liposomes have an average diameter in the range 100 nm-5 μm.

Assignments (2)
SECURITY INTEREST Recorded Sep 15, 2015
From: LIPOXEN TECHNOLOGIES LIMITED
To: OPKO PHARMACEUTICALS, LLC
Reel/Frame 036567/0903 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2002
From: GREGORIADIS, GREGORY
To: LIPOXEN TECHNOLOGIES LIMITED
Reel/Frame 013704/0268 →
Priority Claims (1)
EP 99310032 · Dec 13, 1999 · regional
Continuity (1)
Related Publication 20030078225A1 · Apr 24, 2003